GSK plc (NYSE:GSK) Shares Bought by Signaturefd LLC

Signaturefd LLC boosted its position in shares of GSK plc (NYSE:GSK) by 25.1% during the 4th quarter, Holdings Channel reports. The institutional investor owned 40,090 shares of the pharmaceutical company’s stock after acquiring an additional 8,035 shares during the period. Signaturefd LLC’s holdings in GSK were worth $1,356,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. grew its position in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares during the period. Indiana Trust & Investment Management Co grew its position in GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 500 shares during the period. Crews Bank & Trust acquired a new stake in GSK during the fourth quarter valued at $26,000. ST Germain D J Co. Inc. grew its position in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the period. Finally, Sierra Ocean LLC acquired a new stake in shares of GSK in the fourth quarter valued at about $32,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Performance

NYSE:GSK opened at $40.35 on Wednesday. The company’s 50-day moving average price is $36.30 and its 200-day moving average price is $36.96. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a market cap of $83.51 billion, a P/E ratio of 25.37, a P/E/G ratio of 1.12 and a beta of 0.58. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.93.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, sell-side analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 3.90%. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio (DPR) is currently 98.74%.

Analysts Set New Price Targets

Several analysts have recently issued reports on GSK shares. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.